Javelin Pharmaceuticals, Inc. (NYSE - Amex: JAV) announced today that the registration statement on Form S-4 filed by Myriad Pharmaceuticals, Inc. ("MPI") relating to the proposed merger between Javelin Pharmaceuticals, Inc. ("Javelin") and a subsidiary of MPI was recently declared effective by the Securities and Exchange Commission and mailing of the joint proxy statement/prospectus and Javelin's proxy card contained therein will commence shortly.
Javelin’s Board of Directors has set April 22, 2010 as the date for its Special Meeting of Stockholders to vote on the adoption and approval of the merger agreement and the proposed merger. In addition, the Board of Directors has fixed March 8, 2010 as the record date for the determination of stockholders entitled to notice of, and to vote their proxy at or before, the Special Meeting of Stockholders.
The Special Meeting of Stockholders will be held at 150 CambridgePark Drive, Cambridge, MA 02140 at 2 pm (EDT). The closing of the merger is expected to take place shortly thereafter, subject to satisfaction of the closing conditions outlined in the joint proxy statement/prospectus, including receipt of approval of MPI's stockholders of the issuance of shares of MPI common stock in the merger at MPI's special meeting of stockholders, also scheduled on April 22, 2010.
About Javelin Pharmaceuticals, Inc.:
With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the acute pain management market. The Company has one approved drug in the UK, a submitted NDA for Dyloject and two drug candidates in US Phase III clinical development. For additional information about Javelin, please visit the Company's website at
Javelin Pharmaceuticals, Inc. Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the expected timing of results and development of our drug candidates, the proposed merger between Javelin Pharmaceuticals, Inc. and Myriad Pharmaceuticals, Inc., and potential FDA approval and commercial launch of Dyloject. These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that we may be unable to further identify, develop and achieve commercial success for new products and technologies; the risk that we may be unable to discover drugs that are safer and more efficacious than our competitors; the risk that we may be unable to develop and maintain manufacturing capabilities for our products; the possibility of delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinical trials may not result in marketable products; the risk that we may be unable to successfully finance and secure regulatory approval of and market our drug candidates, or that clinical trials will not be completed on the timelines we have estimated; uncertainties about our ability to obtain new corporate collaborations and acquire new technologies on satisfactory terms, if at all; the development of competing products and services; the risk that we may be unable to protect our proprietary technologies; the risk of patent-infringement claims; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in our Form 10-K, for the year ended December 31, 2009, which was filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Javelin Pharmaceuticals undertakes no duty to update this information unless required by law.